Trailhead Biosystems Raises $6.6 Million in Series A Financing

 Trailhead Biosystems Inc. (www.trailbio.com) - a biotechnology company pioneering the application of machine-enabled science towards understanding and controlling biology - announced its $6.6 million Series A financing. The company has developed a proprietary platform to perform systems-level interrogation of complex biological problems, ranging from the generation of industrially-scalable manufacturing conditions for specialized human cells to combinatorial drug discovery in cancer and anti-viral therapies. Trailhead robotically conducts the largest dimensioned experiments in biology, using machine learning to discover critical process parameters and combinatorial inputs that explain biological responses.  Trailhead's groundbreaking methods depart radically from the limited explorative power of standard hypothesis-driven research.